Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | NNMT | P40261 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | MB | P02144 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2842156 | 0.90 | ASIC3 (0.42) | ASIC3PNMTNNMTGRM5MB | |
| SCHEMBL298258 | 0.79 | NNMT (0.53) | ASIC3PNMTNNMTGRM5DYRK1A | |
| SCHEMBL20595712 | 0.77 | HTT (0.34) | ASIC3NNMTGRM5DYRK1AHTT | |
| SCHEMBL13320529 | 0.77 | NNMT (0.41) | ASIC3PNMTNNMTGRM5MB | |
| SCHEMBL30507029 | 0.76 | NNMT (0.55) | ASIC3PNMTNNMTGRM5DYRK1A | |
| SCHEMBL1258438 | 0.76 | NNMT (0.55) | ASIC3PNMTNNMTGRM5DYRK1A | |
| Bromide SCHEMBL2842948 | 0.76 | NNMT (0.40) | ASIC3NNMTGRM5MBDYRK1A | |
| SCHEMBL2843856 | 0.75 | NNMT (0.50) | ASIC3NNMTGRM5DYRK1AHTT | |
| SCHEMBL18801624 | 0.75 | ASIC3 (0.41) | ASIC3NNMTGRM5MB | |
| SCHEMBL1253776 | 0.74 | MB (0.41) | NNMTMBDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2687533-B1 | Acrylamide derivatives as FAB I inhibitors | DEBIOPHARM INT SA (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-2687533-B1 | Acrylamide derivatives as FAB I inhibitors | DEBIOPHARM INT SA (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-2054422-B1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | DEBIOPHARM INT SA (CH) | 2017-06-14 | — | — | EP | disclosed |
| EP-2054422-B1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | DEBIOPHARM INT SA (CH) | 2017-06-14 | — | — | EP | disclosed |
| US-8895545-B2 | Acrylamide derivatives as Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2014-11-25 | — | — | US | disclosed |
| US-8895545-B2 | Acrylamide derivatives as Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2014-11-25 | — | — | US | disclosed |
| US-8895545-B2 | Acrylamide derivatives as Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2014-11-25 | — | — | US | disclosed |
| EP-2687533-A2 | Acrylamide derivatives as FAB I inhibitors | Affinium Pharmaceuticals, Inc. (CA) | 2014-01-22 | — | — | EP | disclosed |
| EP-2687533-A2 | Acrylamide derivatives as FAB I inhibitors | Affinium Pharmaceuticals, Inc. (CA) | 2014-01-22 | — | — | EP | disclosed |
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | DEBIOPHARM INTERNATIONAL SA (CH) | 2013-10-24 | — | — | US | disclosed |
| US-8318720-B2 | Acrylamide derivatives as Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-11-27 | — | — | US | disclosed |
| US-8318720-B2 | Acrylamide derivatives as Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-11-27 | — | — | US | disclosed |
| WO-2011156811-A2 | COMPOUNDS FOR TREATMENT OF BOVINE MASTITIS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011156811-A2 | COMPOUNDS FOR TREATMENT OF BOVINE MASTITIS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-12-15 | — | — | WO | disclosed |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2054422-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | Affinium Pharmaceuticals, Inc. (CA) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008009122-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009122-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | LPO, MPO, MMP8 | ASIC3 3559/4885PNMT 478/4885NNMT 43/4885 |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | ACR, DBI, AADAC | ASIC3 429/4885PNMT 3947/4885NNMT 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.